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Abstract. Oesophageal cancer is an aggressive tumour which 
responds poorly to both chemotherapy and radiation therapy 
and has a poor prognosis. Thus, a greater understanding of the 
biology of oesophageal cancer is needed in order to identify 
novel therapeutic targets. Among these targets p38 MAPK 
isoforms are becoming increasingly important for a variety of 
cellular functions. The physiological functions of p38α and -β 
are now well documented in contrast to -γ and -δ which are 
comparatively under-studied and ill-defined. A major obstacle 
to deciphering the role(s) of the latter two p38 isoforms is the 
lack of specific chemical activators and inhibitors. In this study, 
we analysed p38 MAPK isoform expression in oesophageal 
cancer cell lines as well as human normal and tumour tissue. We 
observed specifically differential p38δ expression. The role(s) of 
p38δ and active (phosphorylated) p38δ (p-p38δ) in oesophageal 
squamous cell carcinoma (OESCC) was delineated using wild-
type p38δ as well as active p-p38δ, generated by fusing p38δ to 
its upstream activator MKK6b(E) via a decapeptide (Gly-Glu)5 
linker. OESCC cell lines which are p38δ-negative (KE-3 and -8) 
grew more quickly than cell lines (KE-6 and -10) which express 
endogenous p38δ. Re-introduction of p38δ resulted in a time-
dependent decrease in OESCC cell proliferation which was 
exacerbated with p-p38δ. In addition, we observed that p38δ 
and p-p38δ negatively regulated OESCC cell migration in vitro. 
Finally both p38δ and p-p38δ altered OESCC anchorage-inde-
pendent growth. Our results suggest that p38δ and p-p38δ have 
a role in the suppression of OESCC. Our research may provide 
a new potential target for the treatment of oesophageal cancer.
Introduction
Oesophageal cancer is the seventh most common cancer 
worldwide (1) with its 5-year survival rate being dismally 
low at ≤15% (2). Oesophageal squamous cell carcinoma 
(OESCC) is an exceptionally drug-resistant tumour. Despite 
recent advances in the detection of OESCC and the develop-
ment of multimodal therapy (3,4), its incidence is on the rise 
and outcome for patients remains poor (5,6). Thus, a greater 
understanding of the initiation and progression of OESCC is 
required in order to be able to identify predictive and prog-
nostic factors that may in the future lead to novel therapeutic 
strategies.
The mitogen-activated protein kinases (MAPKs) are 
serine/threonine kinases and include the extracellular-
regulated kinase (ERK), c-jun NH2-terminal kinase (JNK) 
and p38 MAPK families. The p38 MAPK family consists 
of four members; p38α (MAPK14) of which there are two 
splice variants (7), p38β (MAPK11), p38γ (MAPK12) and 
p38δ (MAPK13) (8). Although these isoforms are 60-70% 
identical in amino acid sequence they differ greatly in their 
tissue distribution (9), substrate specificity (10) and sensitivity 
to chemical inhibitors (11). In recent years, we have gained an 
increased appreciation of the importance of p38 isoforms for a 
variety of cellular functions including proliferation, differen-
tiation, transformation and programmed cell death (12). Their 
roles, however, are more complex than previously thought, 
with distinct members appearing to have different functions. 
In addition, the roles of p38 in various pathologic conditions 
remain to be elucidated (13).
To-date most of the published literature refers to the 
p38 family as a whole or indeed have focused on the first 
discovered isoform p38α (10,13). There is an obvious dearth 
of research pertaining to the latter two isoforms, p38γ and 
-δ, due partly to the lack of commercially available specific 
chemical activators or inhibitors for each of these isoforms 
(14). In the present study we have overcome this obstacle 
using an enzyme-substrate fusion approach for the generation 
of constitutively active p38δ. We now provide new informa-
tion regarding the role(s) of p38δ and active (phosphorylated) 
p38δ (p-p38δ) in OESCC. We identified differential p38δ 
expression in OESCC. Lack of p38δ expression in OESCC 
allows for a more aggressive phenotype including increased 
proliferation, increased migration and increased capacity for 
anchorage-independent growth. Restoration of p38δ expres-
sion, however, reverses these effects. Together, our results 
provide evidence for a novel role for p38δ-induced suppressive 
effects in OESCC. With survival rates being poor for patients 
with OESCC, there is an urgent need to find novel strategies to 
Loss of p38δ mitogen-activated protein kinase expression 
promotes oesophageal squamous cell carcinoma proliferation, 
migration and anchorage-independent growth
CAROL O'CALLAGHAN1,  LIAM J. FANNING2,  AILEEN HOUSTON2  and  ORLA P. BARRY1
Departments of 1Pharmacology and Therapeutics and 2Medicine, University College Cork, Ireland
Received March 21, 2013;  Accepted May 3, 2013
DOI: 10.3892/ijo.2013.1968
Correspondence to: Dr Orla Patricia Barry, Department of 
Pharmacology and Therapeutics, Room 3.89, Western Gateway 
Building, Western Road, University College Cork, Cork, Ireland
E-mail: o.barry@ucc.ie
Key words: oesophageal cancer, p38δ mitogen-activated protein 
kinase, proliferation, migration, anchorage-independent growth
O'CALLAGHAN et al:  A NOVEL INVESTIGATION OF p38δ MAPK IN OESOPHAGEAL CANCER406
improve current therapy. Our study suggests isoform specific 
activation of p38δ as a possible potential approach for treat-
ment of patients with OESCC.
Materials and methods
Reagents. All chemicals and cell culture reagents were 
purchased from Sigma-Aldrich (Wicklow, Ireland), enzymes 
from New England BioLabs (Hertfordshire, UK) and primary 
antibodies from Cell Signaling Technologies (Hertfordshire, 
UK), unless otherwise stated.
Specimens. The patient cohort consisted of ten patients with 
OESCC of both genders ranging in age from 44 to 81 years. 
Formalin-fixed, paraffin-embedded (FFPE) oesophagectomy 
specimens from ten patients consisted of ten paired samples of 
primary tumour and metastatic lymph nodes with 10 samples 
of non-tumour adjacent tissues (NAT). Patient features are 
summarized in Table IA.
Cell culture. The KE oesophageal cancer cell lines (kind 
gifts from Professor T. Fujii, Kurume University School of 
Medicine, Japan) (15-17) as well as KYSE-70, OE-19, OE-21 
and OE-33 (ATCC, Rockville, MD, USA) were cultured in 
RPMI-1640 supplemented with 10% FCS, 100 µg/ml strep-
tomycin and 100 U/ml penicillin. KE cell line features are 
summarized in Table IB. The metastatic oesophageal cancer 
cell line, OC-3 [a kind gift from Cork Cancer Research Centre, 
(Biosciences Institute, National University of Ireland, Cork, 
Ireland] (18) was cultured in DMEM supplemented with 
10% FCS, 100 µg/ml streptomycin and 100 U/ml penicillin. 
KYSE-450 cells (ATCC, Rockville, MD, USA) were main-
tained in 45% RPMI-1640/45% Ham's F-12 nutrient mixture 
supplemented with 10% FCS, 100 µg/ml streptomycin and 
100 U/ml penicillin.
Proliferation assay. KE cells were plated at a density of 
3x104 cells/well in a 6-well tissue culture plate. Cell viability 
was assessed by trypan blue (0.4% w/v) exclusion assay at the 
indicated times (18).
Nuclear and cytosolic extraction. Nuclear and cytosolic 
fractions were isolated from 2x106 cells using the NE-PER 
Isolation kit (Pierce Biotechnology, Rockford, IL, USA) 
according to the manufacturer's instructions.
Generation of MKK6b-p38δ MAPK, MKK6b(E)-p38δ MAPK 
and MKK6b(E)-p38δDN MAPK fusion proteins. p38δ 
(pcDNA3-FLAG-p38δ) and constitutively active MKK6b 
[pcDNA3-MKK6b(E)] plasmids were a kind gift from 
Professor J. Han (Scripps Research Institute, La Jolla, CA, 
USA) and have previously been described (19). To construct 
the pcDNA3-MKK6b(E)-FLAG-p38δ (p-p38δ) fusion plasmid 
the TAA stop codon of MKK6b(E) was replaced with a unique 
SwaI restriction sequence using a QuikChange Lightening 
Site-Directed Mutagenesis kit (Agilent Technologies) (5'-CAT 
CTTTTGTAAAACTGATTCTTGGAGAATTTAAATCAG 
TGGACTTAATCGGTTGACCCTACTG-3'; 5'-CAGTAG 
GGTCAACCGATTAAGTCCACTGATTTAAATTCTCCAA 
GAATCAGTTTTACAAAAGATG-3'). A PCR generated 
Table I. Patient characteristics, and cell lines used.
A, OESCC patient features
Patient features No. of patients
Gender
 Male   4
 Female   6
Age, median (years) 63 (44-81)
TNM7 stage
 T stage
  T3 10
 N stage
  N1   3
  N2   7
Histological grade
 Well differentiated   1
 Moderately differentiated   6
 Poorly differentiated   3
B, KE (OESCC) cell line features
KE features
Gender
 Male KE-3, -4, -5, -6
 Female KE-8, -10
Age, median (years) 67 (50-71)
TNM7 stage
 T stage
  T1 KE-10
  T3 KE-3, -5, -6, -8
  T4 KE-4
 N stage
  N0 KE-5
  N1 KE-3, -4, -6, -8, -10
Histological grade
 Well differentiated KE-5, -6
 Moderately differentiated KE-3, -10
 Poorly differentiated KE-4, -8
C, p38δ MAPK expression in patient specimens
 p38δ MAPK expression -----------------------------------------------------
Diagnosis Positive  Negative
NAT (n=10) 9 1
OESCC primary (n=10) 6a 4
OESCC nodes (n=10) 2 8
A, Patient features and B, KE features are summarised based on 
gender, age, TNM7 stage and histological stage. Based on the 
TNM7 categorization for oesophageal cancer N1=1-2 lymph nodes 
and N2=3-6 lymph nodes. C, Samples obtained from ten patients 
consisted of ten paired primary tumour and metastatic lymph nodes 
as well as corresponding non-tumour adjacent tissues for analysis of 
p38δ expression. ap38δ expression was considerably lower than in 
the corresponding NAT.
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DraI-DraI fragment encoding FLAG-p38δ with a 5' (Gly-Glu)5 
linker (5'-CCGCGCTTTAAAGGCGAGGGCGAGGG 
CGAGGGCGAGGGCGAGATGGACTACAAGGACGAC 
GAT-3'; 5'-TTGATCTTTAAATTATTACAGCTTCATG 
CCACTTCGT-3') to facilitate folding as previously described 
(20) was ligated to SwaI linearised pcDNA3-MKK6b(E) with 
T4 DNA ligase. The pcDNA3-MKK6b-FLAG-p38δ plasmid 
(inactive MKK6b) was created by the substitution of Glu151 and 
Glu155 with Ser and Thr respectively by site-directed muta-
genesis (5'-TGGAATCAGTGGCTATTTGGTGGACTCTGT 
TGCTAAAACAATTGATGCAGGTTGCAAACCATAC-3'; 
5'-GTATGGTTTGCAACCTGCATCAATTGTTTTAGCAA 
CAGAGTCCACCAAATAGCCACTGATTCCA-3'). The 
pcDNA3-MKK6b(E)-FLAG-p38δDN (dominant negative) 
(p-p38δDN) plasmid was created by substituting Thr180 and 
Tyr182 of p38δ with Ala and Phe respectively by site-directed 
mutagenesis (5'-GACGCCGAGATGGCTGGCTTCGTGG 
TGACCCG-3'; 5'-CGGGTCACCACGAAGCCAGCCAT 
CTCGGCGTC-3'). DNA sequence analysis confirmed the 
integrity of all plasmids.
Stable transfection. KE-3 cells were transfected using 
Lipofectamine™ 2000 reagent (Life Technologies™) and a 
total of 4 µg of plasmid DNA according to the manufacturer's 
instructions. Twenty-four hours following transfection cells 
were transferred to 100-mm diameter dishes and transfected 
cells were selected in growth medium containing 800 µg/
ml Geneticin. After 4-8 weeks, individual cell colonies were 
transferred for clone expansion.
Immunoblot analysis. Supernatants used for immunoblotting 
with specific antibodies, p38α and -δ, phospho-p38 MAPK 
and MKK6 antibodies (New England Biolabs), p38γ (Upstate) 
and p38β2 antibody (Zymed Laboratories Inc.) have previously 
been described by us (18,21). Chemiluminescent detection was 
performed using SuperSignal® WestDura Extended Duration 
Substrate (Pierce Biotechnology) and bands were visualized 
using a Syngene G:Box ChemiXR5 Gel Documentation 
System.
Immunohistochemistry. This was performed as previously 
described by us (21). Briefly, FFPE OESCC and NAT sections 
were de-parrafinized in xylene and re-hydrated prior to anal-
ysis. Antigen retrieval was performed by microwave irradiation 
in 0.01 M citrate buffer, pH 6.0. In addition cultured cells 
grown on coverslips were fixed in 2-4% paraformaldehyde and 
permeabilised with 0.5% Triton-X-100. Samples were blocked 
with 5% NGS in TS/SAP. Slides were incubated with primary 
antibody overnight at 4˚C. Antibody binding was localized 
using a biotinylated secondary antibody, avidin-conjugated 
HRP and DAB substrate, contained within the Vectastain 
ABC detection kit (Vector Laboratories, Burlingame, CA, 
USA). Slides were counterstained with hematoxylin.
ELISA. Cell lysates were analysed for p38δ phosphorylation 
at T180/Y182 using the R&D Systems DuoSet® IC Human 
phospho-p38δ (T180/Y182) sandwich ELISA (DYC2124-5) 
according to the manufacturer's instructions. Absorbance was 
read at 450 nm on a Tecan Sunrise spectrophotometric plate 
reader and analysed using the XRead software program.
Boyden chamber cell migration assay. Cells were plated 
in starvation medium at a density of 3x104 cells/well into a 
96-well plate of the upper chamber. The bottom chamber 
contained 10% FCS as the chemoattractant. Cells were left 
migrate for 24 h through the matrigel filter (8 mm). Migrated 
cells were treated with MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) (5 mg/ml) and absorbance 
read at 540 nm to calculate viable cell numbers as previously 
described (21).
Wound-healing assay. Cell migration was assessed by in vitro 
wound-healing assay as previously described (22). A linear 
wound track was made by use of a sterile tip through confluent 
cells. Cells migrating into the wound were captured under 
a phase-contrast microscope 24 and 48 h after wounding. 
Migration was determined using the ImageJ program as an 
average closed area of the wound relative to the initial wound 
area at 24 and 48 h after wounding.
Colony forming assay. The role of p38δ in anchorage-inde-
pendent growth was assayed using a soft agar colony-forming 
assay as previously described (21). Cells were plated at a 
density of 3x105 cells/100-mm dish in medium containing 
0.4% (w/v) agar on an underlay of 0.8% (w/v) agar. After a 
21-day incubation colonies were stained with MTT (5 mg/ml) 
overnight and counted.
siRNA. KE-6 cells at 75% confluency in antibiotic-free media 
were transfected with 100 nM p38δ MAPK siRNA or control 
siRNA-A (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
according to the manufacturer's instructions and as recently 
described (23).
RT-PCR. First-st rand cDNA was synthesised using 
SuperScript® VILO™ cDNA Synthesis kit (Life Technologies) 
from total RNA isolated from cells using an Illustra RNASpin 
Mini kit (GE Healthcare, Buckinghamshire, UK) according to 
the manufacturer's instructions. p38δ mRNA was amplified 
from cellular cDNA under the following conditions: ddH2O, 
1X DreamTaq buffer, 0.2 mM dNTPs, 0.25 µM p38δ forward 
primer: 5'-CCACGTTAAACTGCCCATCT-3', 0.25 µM p38δ 
reverse primer: 5'-CCGCCACAAGCTAAAAAGAG-3', 1 µl 
cDNA and 1 U DreamTaq DNA polymerase (Thermo Fisher 
Scientific; Waltham, MA, USA). RT-PCR products were anal-
ysed by agarose gel electrophoresis.
Proteome Profiler™ antibody array. The relative levels of 
phosphorylation of 26 kinases was examined in cell lysates 
using a Proteome Profiler Human Phospho-MAPK array 
(R&D Systems, Abingdon, UK) according to the manufac-
turer's instructions. Following chemiluminescent detection, 
pixel density of each spot was analysed using Scion image 
software.
Ethics. The research was approved by the Clinical Research 
Ethics Committee of the Cork Teaching Hospitals.
Statistical analysis. Results are expressed as mean ± SE. 
Statistical comparisons were made by using analysis of 
variance with subsequent application of Student's t-test, as 
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appropriate. GraphPad InStat 3 software was used also for 
statistical analysis.
Results
p38α, -β, -γ and -δ isoforms and MKK3, -4, -6 and 7 are 
differentially expressed in oesophageal cancer. The expres-
sion of p38 as a family has previously been outlined in 
oesophageal cancer as well as other cancer types (10,13,24,25). 
While these reports refer to the p38 family, analysis of indi-
vidual p38 isoform expression in oesophageal cancer has to 
date never been reported. A previous study by us outlining 
differential p38 isoform expression in renal cancer prompted 
us to investigate further the effects of individual p38 family 
members in cancer in general (26). Using western blot analysis 
we examined p38 MAPK isoform expression in nine OESCC 
cell lines (KE-3, -4, -5, -6, -8, -10, KYSE-70, KYSE-450 and 
OE-21) and three oesophageal adenocarcinoma cell lines 
(OC-3, OE-19 and OE-33). We used antibodies specific for 
each isoform p38α, -β2, -γ and -δ as previously described by us 
(26). All twelve oesophageal cancer cell lines (squamous and 
adenocarcinoma) expressed p38α, -β and -γ (albeit at different 
levels) (Fig. 1A). In contrast p38δ expression was present in 
the three adenocarcinoma cell lines but absent in four of the 
OESCC cell lines KE-3, -8, KYSE-70 and OE-21 (Fig. 1A). 
The specific loss of p38δ isoform expression only has previ-
ously been reported by us in renal carcinoma (786-0) (26) and 
also observed by us in liver (Huh-7), lung (A-549) prostate 
(PC-3 and DU-145) and skin (MeWo) cancer cell lines (Barry 
et al, unpublished data). Upstream MKK3 and -6 are thought 
to be the major protein kinases responsible for p38 activation 
(24) but the selectivity of p38 isoform activation is stimulus 
type and strength dependent (27). We observed strong MKK3 
and -4 expression for all cell lines except KE-3 and -8 OESCC 
which were MKK3 negative. In contrast levels of MKK6 
and -7 expression were considerably lower (Fig. 1B).
Finally, analysis of p38δ at the mRNA level surprisingly 
proved positive for all cell lines examined including the four 
OESCC cell lines that were negative for p38δ protein expres-
sion (Fig. 1C). Primers specific for a 292-bp fragment of the 
3'-untranslated region of p38δ mRNA amplified cDNA from 
all twelve cell lines. Other primer sets within the coding 
sequence yielded similar results (data not shown). In addition 
DNA sequence analysis of PCR products did not identify any 
mutations such as a stop codon or a missense mutation which 
could possibly explain loss of p38δ protein expression (data 
not shown).
To investigate whether the p38 isoform expression pattern 
we observed in vitro with the OESCC cell lines could be 
translatable to the in vivo situation we analyzed the expres-
sion profile and localization of all four p38 isoforms (α, 
-β, -γ and -δ) in FFPE oesophagectomy specimens from 
ten patients with squamous cell carcinoma. Samples consisted 
of ten paired primary tumour and metastatic (lymph nodes) 
as well as corresponding non-tumour adjacent tissues (NAT) 
as outlined in Table IA. Samples were staged according to the 
new TNM7 categorization for oesophageal cancer (Table IA) 
(28). Consistent levels of p38α and -β expression was evident 
in all ten normal, primary and metastatic OESCC samples 
(Fig. 1D). Similarly, we did not observe a change in p38γ 
expression between normal, primary tumour and metastatic 
samples albeit the intensity of brown staining was less than that 
Figure 1. Expression of p38 MAPK isoforms, MKK3, -4, -6 and -7 in oesophageal cancer. (A) Western blot analysis of p38 isoform expression in KE-3, -4, -5, 
-6, -8 and -10, KYSE-70, -450 and OE-21 (oesophageal squamous cell carcinoma cell lines) as well as OC-3, OE-19 and OE-33 (oesophageal adenocarcinoma 
cell lines). (B) Western blot analysis of MKK3, -4, -6 and -7 in the same twelve cell lines. Aliquots of 30 µg of protein lysate were loaded on a 10% SDS-PAGE 
gel and analyzed by immunoblotting using antibodies specific for p38α, -β2, -γ and -δ. β-actin analysis served as a loading control. The results shown are 
representative of four independent experiments. (C) Agarose gel electrophoresis analysis of DNA fragments produced by PCR amplification of p38δ mRNA 
from oesophageal squamous (KE3, -4, -5, -6, -8, 10, KYSE70, -450 and OE21) and adenocarcinoma (OC3, OE19 and -33) cell lines. (D) Immunohistochemical 
staining of p38α, -β2, -γ and -δ isoforms in normal, tumourigenic and metastatic (lymph node) oesophageal human tissue. Immunohistochemical staining was 
performed as outlined in Materials and methods. Blue arrow indicates cytoplasmic staining; black arrow indicates nuclear staining; white arrow indicates blue 
unstained nuclei and yellow arrow indicates blue unstained cytoplasm. Magnification, x400. The results shown are representative of ten patients.
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observed for p38α and -β (Fig. 1D). p38δ expression, however, 
was considerably different in normal vs primary tumour vs 
metastatic disease (Fig. 1D and Table IC). p38δ expression 
was observed in both the nuclei and cytoplasm of nine of the 
ten oesophageal NAT tissue samples. However, a significant 
decrease in expression was observed in both the nuclei and 
cytoplasm in the ten primary tumour specimens as evidenced 
from the lighter brown staining compared to NAT samples in 
six patient samples and complete loss of expression in four of 
the samples (Fig. 1D and Table IC). Furthermore, eight out 
of the ten metastatic tissue specimens demonstrated complete 
loss of p38δ expression with both the nuclei and cytoplasm 
appearing blue in colour (Fig. 1D). This is an important 
finding considering identification of lymph node metastasis 
is the single most important prognostic factor in oesophageal 
cancer (1).
OESCC cell lines lacking endogenous p38δ MAPK expres-
sion proliferate faster than those which express this isoform. 
The results obtained for differential p38δ expression in both 
the oesophageal cell lines and the human samples prompted 
us to investigate further the effect(s) if any this particular 
isoform may have on the tumourigenicity of OESCC. Firstly, 
we examined whether the absence or presence of endogenous 
p38δ expression could have an effect on the proliferation rate 
of our OESCC cell lines. Using the trypan blue exclusion 
assay we compared the proliferation rate of KE-3 and -8 cell 
lines (which do not express p38δ) versus KE-6 and -10 (which 
express p38δ). We observed that at all time-points studied 
(24-120 h) both cell lines KE-3 and -8 proliferated faster than 
KE-6 and -10 cells (Fig. 2).
Generation of active (phosphorylated) p38δ (p-p38δ) MAPK 
fusion proteins. To investigate whether p38δ or active (phos-
phorylated) p38δ (p-p38δ) drives the observed anti-proliferative 
phenotype (Fig. 2) we re-introduced wild-type p38δ into KE-3 
cells which have lost its expression. In the absence of a specific 
commercially available p38δ activator [and to investigate the 
effect(s) of active (p-p38δ)] we generated a constitutively 
active p38δ through enzyme substrate fusion as previously 
described for JNK (Fig. 3A) (20). Western blot analysis of 
stable transfections of KE-3 cells demonstrated that pcDNA3-
MKK6b-(Gly-Glu)5-FLAG-p38δ (data not shown) as well as 
pcDNA3-MKK6b(E)-(Gly-Glu)5-FLAG-p38δ both produced 
a single polypeptide with a molecular mass of 82 kDa as 
expected when using p38δ, p-p38 and MKK6 antibodies, 
respectively (Fig. 3B). As both MKK6b and MKK6b(E) fused 
in frame to p38δ produced the same desired result only one 
plasmid (MKK6b(E)-p38δ) was used for subsequent experi-
ments. Western blot analysis of KE-3 cells stably transfected 
with pcDNA3-MKK6b(E)-(Gly-Glu)5-FLAG-p38δDN also 
produced a single polypeptide with a molecular mass of 
82 kDa upon incubation with p38δ and MKK6 antibodies 
(Fig. 3Bi and iii) but did not demonstrate p38 activation (phos-
phorylation) (Fig. 3Bii). Of note the antibody used in Fig. 3Bii 
is a pan phospho-p38 antibody. To our knowledge there is no 
commercially available antibody to test for active (phosphory-
lated) p-p38δ specifically by western blot analysis. Therefore, 
to confirm p38δ activation we performed a sandwich ELISA 
which measures p38δ isoform phosphorylation specifically. 
Transfection of KE-3 cells with wild-type p38δ alone revealed 
activation (Fig. 3C). This is in strong agreement with previous 
reports where adenovirally expressed wild-type p38δ was 
activated in head and neck squamous cell carcinoma (29) 
and human keratinocytes (30). A 4-fold (p<0.001) increase in 
activation of p38δ was observed following stable transfection 
of KE-3 cells with p-p38δ (Fig. 3C). This level of activation 
is similar to KE-3 p38δ transfected cells upon activation with 
anisomycin (30 µM) (data not shown). As expected we did 
not observe phosphorylation of p38δ in cells transfected with 
p-p38δDN (Fig. 3C). We also analysed KE-6 and KE-10 cell 
lines (which express endogenous p38δ expression) but did not 
observe p38δ phosphorylation in either cell line (Fig. 3C).
To ensure specific phosphorylation of p38δ only and not 
the other three p38 isoforms (α, -β and -γ) we performed a 
human phospho-MAPK antibody array (R&D Systems). We 
did not observe phosphorylation of p38α, -β or -γ in non-
transfected KE-3 cells or cells stably transfected with p38δ or 
p-p38δ (Fig. 3D and E). We did, however, observe an increase 
(p<0.001) in phosphorylation in KE-3 p38δ wild-type trans-
fected cells which was amplified in KE-3 p-p38δ transfected 
cells (Fig. 3D and E) in agreement with our ELISA results 
(Fig. 3C). These results confirm phosphorylation of p38δ only 
in our studies. We also observed MKK6 phosphorylation in 
KE-3 p-p38δ as expected (Fig. 3D and E). A previous report 
outlined p38δ induced inactivation of ERK1/2 (31) however, 
we did not find any change in ERK1/2 or indeed JNK1/2/3 
(Fig. 3D and E).
Finally, the physical location of a protein either in the 
nucleus or the cytoplasm directly influences its biological 
function. Members of the p38 family do not contain either a 
nuclear localisation signal (NLS) or a nuclear export signal 
(NES) but their subcellular localisation can be regulated in part 
by their interacting proteins (32). We compared the subcellular 
localization of p38δ and p-p38 in KE-3 transfected cells with 
endogenous p38δ expression in KE-6 cells. As expected p38δ 
Figure 2. Oesophageal squamous cell carcinoma cell lines lacking endog-
enous expression of p38δ MAPK have a higher proliferation rate. KE-3 and 
-8 cell lines (lacking endogenous p38δ expression) and KE-6 and -10 cell 
lines (expressing endogenous p38δ expression) were seeded (3x104) and 
counted for 24-120 h. The results shown are mean ± SE of three independent 
experiments.
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Figure 3. Generation of active p38δ (p-p38δ) MAPK fusion proteins. (A) A schematic representation of MKK6b-p38δ or MKK6b(E)-p38δ MAPK fusion 
protein. The coding region of p38δ was fused in frame to the 3'-end of the stop codon-less MKK6b or MKK6b(E) through a peptide linker (Gly-Glu)5. 
(B) Western blot analysis of KE-3 cells stably transfected with empty vector (pcDNA3), wild-type p38δ, p-p38δ and p-p38δDN. Cells were analysed by immu-
noblot using antibodies specific for p38δ (i), p-p38 (ii) and MKK6 (iii). Aliquots of 30 µg protein lysate for each cell line were loaded on a 10% SDS-PAGE 
gel. The results shown are representative of four independent experiments. (C) Transfected and non-transfected KE-3, KE-6 and KE-10 cells were analysed to 
determine the amount of activated i.e., phosphorylated p38δ expression using the human phospho-p38δ (T180/Y182) ELISA commercial kit (R&D Systems). 
The ELISA assay was carried out according to the manufacturer's protocol. The results shown are mean ± SE of three independent experiments. Significant 
(***p<0.001) changes from control non-transfected KE-3 cells. (D) The human phospho-MAPK array shows the effects of stably transfecting KE-3 cells with 
p38δ and p-p38δ. Arrays were incubated with 200 µg of cell lysate. (E) Corresponding pixel density for p38α, -β, -δ and -γ, MKK-6, ERK1/2 and JNK1/2/3 
phosphorylation in non-transfected and transfected KE-3 cells. (F) Immunohistochemical subcellular localization of p38δ and p-p38 in KE-3 non-transfected 
cells and cells transfected with p38δ and p-p38δ. KE-6 cells were or were not treated with anisomycin (30 µM). (G) Nuclear and cytoplasmic localization of 
p38δ and p-p38 in KE-3 and KE-6 cells. The results shown are representative of four independent experiments (F and G).
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and p-p38 were absent from both compartments in non-trans-
fected KE-3 cells (Fig. 3F). p38δ and p-p38 were detected in 
both the cytoplasm and the nucleus of KE-3 stably transfected 
cells (Fig. 3F). This pattern of expression correlated with the 
subcellular localization of p38δ and p-p38 in KE-6 cells in the 
presence and absence of anisomycin (30 µM). To confirm our 
immunohistochemical findings cytosolic and nuclear extracts 
were prepared from transfected and non-transfected KE-3 and 
KE-6 cells and examined by western blot analysis. The use of 
PARP as a nuclear-restricted marker and Paxillin as a cyto-
solic marker ensured that there was no cross contamination 
between the subcellular fractions (21). Similar results were 
observed demonstrating the presence of p38δ and p-p38 in 
both the cytoplasm and nucleus of KE-3 and -6 cells (Fig. 3G).
KE-3 cells transfected with p38δ and p-p38δ MAPK show 
reduced proliferation. Uncontrolled cellular proliferation is a 
hallmark of cancer. To investigate if loss of p38δ expression 
specifically drives the higher growth kinetics observed in 
Fig. 2 we compared the growth rates of KE-3 non-transfected 
and transfected cells. We observed a significant (p<0.001) 
time-dependent decrease in the proliferation rate of KE-3 cells 
when transfected with wild-type p38δ compared with non-
transfected cells and cells transfected with empty pcDNA3 
vector (Fig. 4A). This anti-proliferative effect was amplified 
further in KE-3 cells transfected with active p-p38δ (Fig. 4A). 
KE-3 cells transfected with p-p38δDN demonstrated the same 
proliferation rate as non-transfected cells or cells transfected 
with pcDNA3 only (Fig. 4A).
To further examine the hypothesis that p38δ is anti-
proliferative in OESCC we employed a siRNA approach using 
the KE-6 cell line which expresses endogenous p38δ (Figs. 1, 
3F and G). KE-6 cells were transiently transfected with p38δ 
siRNA or control siRNA as previously described (23). We 
Figure 4. Effect of p38δ and p-p38δ MAPK expression on cell proliferation. (A) KE-3, KE-3 pcDNA3, KE-3 p38δ, KE-3 p-p38δ and KE-3 p-p38δDN cells were 
seeded (3x104) and counted for 24-120 h. The results shown are mean ± SE of three independent experiments. Significant (***p<0.001) changes from control 
non-transfected KE-3 cells. (B) Western blot analysis of KE-6 cells transiently transfected or not transfected with p38δ siRNA or control siRNA for 24-96 h. 
Cells were analysed by immunoblotting using a p38δ antibody. Aliquots of 30 µg protein lysate were loaded on a 10% SDS-PAGE gel. The results shown are 
representative of three independent experiments. (C) Densitometric analysis was performed to analyse % knockdown of KE-6 p38δ protein. (D) KE-6 cells 
(3x104) transfected with p38δ siRNA or control siRNA were seeded and counted for 24-96 h. The results shown are mean ± SE of three independent experi-
ments each done in triplicate. Significant (***p<0.001) changes from control siRNA transfected KE-6 cells.
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observed a 51.9±6.5% reduction in KE-6 p38δ expression 
at 24 h following p38δ siRNA transfection which increased 
to 72.6±2.6% by 96 h when compared to control siRNA 
transfected KE-6 cells (Fig. 4B and C). No change in p38δ 
expression was observed when KE-6 cells were transfected 
with control siRNA for all time-points studied (24-96 h) (only 
24 h is shown in Fig. 4B). A significant (p<0.001) increase in 
cell proliferation was observed for KE-6 cells transfected with 
p38δ siRNA compared to cells transfected with control siRNA 
for all time-points studied (Fig. 4D). The anti-proliferative 
Figure 5. Effect of p38δ and p-p38δ MAPK on KE-3 cell migration and anchorage-independent growth. KE-3, KE-3 pcDNA3, KE-3 p38δ, KE-3 p-p38δ and 
KE-3 p-p38δDN cells were analysed for cell migration (A-C) and anchorage-independent growth D). (A and B) p38δ and p-p38δ inhibit KE-3 migration at 
24 h (A, Boyden Chamber) and 24 and 48 h (B, wound healing). (C) Representative wound healing images at 0, 24 and 48 h. Wound healing rates decrease in 
p38δ and p-p38δ transfected KE-3 cells. The results shown are representative of three independent experiments. (D) Anchorage-independent growth potential 
of KE-3 non-transfected and transfected cells were measured by their ability to form colonies on soft agar. Plates were stained with 3-(4,5-dimethylthiazol-
2-yl)-2, 5-diphenyl tetrazolium bromide to visualize colonies. The number of colonies per plate is shown. The results shown are mean ± SE of four independent 
experiments (A, B and D). Significant (**p<0.01; ***p<0.001) changes from control non-transfected KE-3 cells.
INTERNATIONAL JOURNAL OF ONCOLOGY  43:  405-415,  2013 413
effect was observed even in the absence of active p38δ in 
KE-6 cells (Fig. 3C). This effect on proliferation may be inde-
pendent of its kinase activity as has previously been reported 
for p38α in regulating HeLa cell proliferation (33) and p38γ in 
rat intestinal epithelial cells (34).
p38δ and p-p38δ MAPK play a role in migration and 
anchorage-independent growth of KE-3 cells. A key charac-
teristic of cancer cells is their ability to migrate and progress 
from primary tumours to metastases in distant organs. A 
recent report summarizes the roles of p38 MAPKs in cancer 
invasion and metastasis (35). This review, however, as in 
previous reports documents the roles of p38 family as a whole 
or p38α (10,13). We examined the role of p38δ in OESCC 
cell migration using both a Boyden chamber assay and a 
wound healing assay. We observed a 66±7.5 and 88.7±1.9% 
decrease in migration after 24 h for KE-3 p38δ and p-p38δ 
cells respectively compared to non-transfected cells (Fig. 5A). 
In addition p38δ and p-p38δ induced a significant decrease in 
KE-3 migration at 24 h [55.65±1.5 and 75.65±0.3% (p<0.001), 
respectively] and 48 h [37.9±0.8, (p<0.01) and 82.7±1.4%, 
(p<0.001) respectively] compared with non-transfected KE-3 
cells using a wound healing assay (Fig. 5B and C). Finally, 
to further examine the influence of p38δ and p-p38δ on the 
growth characteristics of KE-3 cells, we measured their ability 
to grow in an anchorage-independent manner. Non-transfected 
KE-3 cells growing in soft agar for 21 days gave rise to 175±18 
colonies/plate (Fig. 5D). This was similar to the number of 
colonies/plate that grew for cells transfected with empty vector 
(160±20) or p-p38δDN (177±21) (Fig. 5D). In contrast, however, 
p38δ and p-p38δ transfected cells produced a significant 
(p<0.001) decrease in colony numbers in p38δ transfected 
cells (13±3) with no colonies observable for p-p38δ transfected 
cells (Fig. 5D).
Discussion
Oesophageal cancer is a highly aggressive treatment-refrac-
tory disease with a high mortality rate (2,5,6). As conventional 
therapy is ineffective, targeting specific potential molecular 
tumour markers may prove to be the future of oesophageal 
cancer treatment. Despite current studies of molecular targets 
in oesophageal cancer (36), we are still somewhat hindered by 
limited knowledge of the genes and pathways involved in the 
tumourigenesis of the oesophagus when it comes to treatment.
Emerging role(s) for p38 MAPKs in different aspects of 
cancer has recently been outlined. To-date the best studied and 
reviewed isoform in cancer is p38α. It has been characterized 
as both a potential tumour suppressor (25,37-39) and tumour 
promoter (29,35). In comparison the role(s) of p38δ in cancer 
is largely uncharacterised. The limited current knowledge 
pertaining to p38δ, however, also alludes to disparate role(s) 
for this kinase in tumour development. An oncogenic role 
for p38δ has been suggested in p38δ-deficient mice that have 
reduced susceptibility to skin carcinogenesis (40) as well as 
promoting head and neck squamous carcinoma cell growth 
(29). In contrast a very recent study outlined a role for p38δ 
as a tumour suppressor in mouse fibroblasts (41). In our 
study outlined here we show for the first time the differential 
expression of p38δ in OESCC cell lines and in vivo. The loss 
of p38δ expression provides a survival advantage for OESCC 
which demonstrates increased cell proliferation, migration and 
contact inhibition. Re-introduction of p38δ, however, leads to 
reversal of these tumourigenic effects. Thus, recent evidence 
(41) as well as our present study suggests that targeting p38δ 
may offer a powerful protection against carcinogenesis. 
Targeting p38 MAPK isoforms or pathways for therapeutic 
purposes, however, should perhaps be strictly dependent on 
cell context, tumour cell type and tumour stage.
The fusion of p38δ to its upstream kinase MKK6b or 
active MKK6b [MKK6b(E)] generated a constitutively active 
p38δ which was used as a tool to study its specific effect(s) 
in OESCC. Re-introduction of p38δ (with subsequent acti-
vation) or active p-p38δ into KE-3 OESCC attenuated cell 
proliferation, migration and anchorage-independent growth. 
The strength and duration of p38 activation has been shown 
to play a crucial role in determining cell fate. Strong activa-
tion has been shown to induce apoptosis whereas lower levels 
results in cell survival (27,39). In our study we observed strong 
anti-proliferative, anti-migratory effects as well as effects on 
anchorage-independent growth upon re-introduction of p38δ 
into KE-3 cells which subsequently became active. These 
antitumourigenic effects were amplified further in KE-3 cells 
transfected with constitutively active p-p38δ. It is possible that 
owing to the localization of both p38δ and p-p38δ in the nucleus 
and the cytoplasm of OESCC that this kinase may modify its 
target(s) either structurally or subcellularly. We are presently 
researching whether they are in free form or docked with 
specific cytoplasmic or nuclear partners (24). Furthermore, 
p38δ and p-p38δ induced antitumourigenic effects in OESCC 
may arise by a combination of both phosphorylation-dependent 
and independent effects as previously described (33,34).
There are many paradigms in the literature of cross-talk 
between different MAPK pathways. In this instance, however, 
when KE-3 cells were stably transfected with p38δ or p-p38δ 
we did not observe changes in either p38 isoform (α, -β and -γ), 
ERK1/2 or JNK1/2/3 expression (data not shown) or activa-
tion levels. This is in agreement with a recent bio-informatics 
analysis of MAPK pathways which specifically identified 
that persistent activation of p38δ is resistant to interaction 
with other MAPKs (42). This lack of interference from other 
MAPKs permits us to specifically study the effects of p38δ on 
cell cycle control, pathway components and regulatory mecha-
nisms in OESCC which is currently ongoing in our laboratory. 
In addition negative feedback mechanisms have been shown to 
contribute to fine-tuning p38 MAPK activity levels. One such 
report outlines an increase in MKK6 expression and stability 
in p38α-/- cardiomyocytes from transgenic mice (43). We did 
not observe a correlation between the presence or absence of 
p38δ expression in OESCC cells and MKK expression. Of 
notable exception is MKK3 whose expression is absent from 
KE-3 and -8 cells (both negative for p38δ) but present in KE-4, 
-5, -6 and -10 cells (all positive for p38δ). However, this pattern 
of expression does not hold for KYSE-70 and OE-21 OESCC 
cell lines which express MKK3 but are also negative for p38δ 
protein expression.
Reports of the involvement of p38 MAPKs in a variety 
of different pathological conditions is continuing to increase 
fuelling interest in the development of potent and specific 
drugs for modulating the activity of these kinases. Presently 
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there are a number of p38 inhibitors undergoing clinical trials 
for the treatment of inflammatory diseases (44,45). Results 
arising from our study demonstrate that loss of p38δ expres-
sion in OESCC provides a more sinister phenotype with 
increased proliferation, migration and anchorage-independent 
growth. Thus, it is possible that isoform specific activation 
(rather than inhibition) of p38δ may provide a therapeutic 
benefit for patients with OESCC which express this isoform. 
In addition, how p38δ activators may interact and enhance 
the effectiveness of traditional therapeutics in combination 
therapy warrants attention.
In conclusion, our results reveal previously undocumented 
p38δ differential expression and function in OESCC. We iden-
tified a subset of OESCC cell lines as well as human primary 
and metastatic tumour samples that exhibit downregulation of 
p38δ protein expression. We now provide evidence that loss of 
expression of this particular isoform may be a mechanism by 
which OESCC cells promote carcinogenesis. Re-introduction 
of p38δ into OESCC negative cell lines suppressed different 
aspects of tumourigenesis. Our data warrant further inves-
tigation to understand the important physiological and 
pathophysiological effects of p38δ in OESCC and is currently 
in progress. This knowledge should identify which pathways, 
substrates or regulators are affected specifically by p38δ in 
providing an antitumourigenic effect in OESCC. Armed with 
this information uncovering novel targets and the develop-
ment of new therapeutics may be possible for this common 
cancer that continues to demonstrate a generally poor clinical 
outcome.
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